Splenic marginal zone lymphoma data in mutated immunoglobulin heavy chain gene cases
| Case . | VH gene . | ID (%) . | Karyotype . | LOH 7q . | CD38 . | IgD . | Months . | Progression . | Follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 5 | VH1-2 | 97.21 | Yes | + | + | 61 | Yes | DOD | |
| 5 | VH3-8 | 96.41 | |||||||
| 33 | VH1-2 | 93.4 | 46XY | No | − | + | 42 | Yes | AWD |
| 365 | VH1-2 | 95.96 | + | + | 40 | Yes | AWD | ||
| 374 | VH1-2 | 97.3 | − | − | 9 | No | AWD | ||
| 376 | VH1-2 | 96.4 | − | + | 33 | No | AWD | ||
| 247 | VH1-69 | 92.38 | 45X,−Y(5)/46X,−Y,+3(4)/46XY(14) | + | + | 3 | Yes | DOD | |
| 85 | VH1-2 | 100 | No | − | + | 56 | No | AWD | |
| 85 | VH4-3 | 96.35 | |||||||
| 293 | VH3-30 | 98.66 | + | + | 22 | No | AWD | ||
| 293 | VH1-2 | 96.41 | |||||||
| 380 | VH1-2 | 97.1 | − | − | 6 | No | AWD | ||
| 377 | VH3-30 | 90.0 | − | + | 32 | No | AWD | ||
| 367 | VH3-23 | 97.76 | 46XX, del(7)(q32) | 3 | No | AWD | |||
| 371 | VH3-7 | 88.0 | 46XY | 15 | No | AWD | |||
| 222 | VH3-74 | 90.62 | − | − | 40 | No | A, CR | ||
| 225 | VH3-30 | 95.98 | 46XX, del(9)(p13p23) | No | − | + | 18 | Yes | DOD |
| 12 | VH4-34 | 96.35 | No | + | − | 53 | No | AWD | |
| 253 | VH4-34 | 92.76 | 49XY, +3,+12, +19 | + | + | 43 | No | AWD | |
| 202 | VH4-34 | 89.95 | 46XX,t(2;17) | + | 36 | No | AWD | ||
| 364 | VH6-1 | 96.0 | − | + | 13 | No | AWD |
| Case . | VH gene . | ID (%) . | Karyotype . | LOH 7q . | CD38 . | IgD . | Months . | Progression . | Follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 5 | VH1-2 | 97.21 | Yes | + | + | 61 | Yes | DOD | |
| 5 | VH3-8 | 96.41 | |||||||
| 33 | VH1-2 | 93.4 | 46XY | No | − | + | 42 | Yes | AWD |
| 365 | VH1-2 | 95.96 | + | + | 40 | Yes | AWD | ||
| 374 | VH1-2 | 97.3 | − | − | 9 | No | AWD | ||
| 376 | VH1-2 | 96.4 | − | + | 33 | No | AWD | ||
| 247 | VH1-69 | 92.38 | 45X,−Y(5)/46X,−Y,+3(4)/46XY(14) | + | + | 3 | Yes | DOD | |
| 85 | VH1-2 | 100 | No | − | + | 56 | No | AWD | |
| 85 | VH4-3 | 96.35 | |||||||
| 293 | VH3-30 | 98.66 | + | + | 22 | No | AWD | ||
| 293 | VH1-2 | 96.41 | |||||||
| 380 | VH1-2 | 97.1 | − | − | 6 | No | AWD | ||
| 377 | VH3-30 | 90.0 | − | + | 32 | No | AWD | ||
| 367 | VH3-23 | 97.76 | 46XX, del(7)(q32) | 3 | No | AWD | |||
| 371 | VH3-7 | 88.0 | 46XY | 15 | No | AWD | |||
| 222 | VH3-74 | 90.62 | − | − | 40 | No | A, CR | ||
| 225 | VH3-30 | 95.98 | 46XX, del(9)(p13p23) | No | − | + | 18 | Yes | DOD |
| 12 | VH4-34 | 96.35 | No | + | − | 53 | No | AWD | |
| 253 | VH4-34 | 92.76 | 49XY, +3,+12, +19 | + | + | 43 | No | AWD | |
| 202 | VH4-34 | 89.95 | 46XX,t(2;17) | + | 36 | No | AWD | ||
| 364 | VH6-1 | 96.0 | − | + | 13 | No | AWD |
VH indicates variable region of the heavy chain; ID, identity frequency; LOH, loss of heterozygosity; IgD, immunoglobulin D; Months, follow-up months; Progression, clinical progression; AWD, alive with disease; DOD, died of disease; A, alive; CR, complete remission.